Navigation Links
Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
Date:4/23/2009

FOXA1 biomarker predicts likelihood of recurrence and long-term disease-free survival of breast cancer patients; Further strengthens Company's breast cancer menu

ALISO VIEJO, Calif., April 23 /PRNewswire-FirstCall/ -- Clarient, Inc., (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has been granted an exclusive intellectual property license from the Indiana University Research and Technology Corporation (IURTC) for the rights to commercialize the FOXA1 biomarker, which predicts the likelihood of recurrence and long-term, disease-free breast cancer survival. The licensing of this intellectual property further strengthens Clarient's deep menu of molecular tests for breast cancer and will complement the Clarient Insight(R) Dx Breast Cancer Profile, which is expected to be released soon.

The FOXA1 marker, also known as forkhead box A1, is a gene known to cause breast cancer. Recent data presented at the 2009 USCAP (United States and Canadian Academy of Pathology) meeting demonstrated that the expression of FOXA1, now known to be an estrogen receptor associated transcription factor, correlated with Oncotype Dx(R) when performed in patient samples from Indiana University. In this clinical study of 79 ER-positive, node-negative breast cancer patients, researchers found that FOXA1 expression identified the same low risk, ER-positive, node-negative patients who can be spared toxic chemotherapy (P=0.002). Researchers concluded Oncotype Dx and the FOXA1 marker can potentially be used interchangeably if further validation studies confirm t
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
2. Clarient to Commercialize Novel Breast Cancer Profile
3. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
4. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
5. Jim Agnello to Resign as Clarient Chief Financial Officer
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
8. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
11. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 RXi Pharmaceuticals Corporation (NASDAQ: ... developing innovative therapeutics, primarily in the areas of dermatology ... offering of 26 million units at a price to ... of approximately $10.4 million. Each unit consists of (i) ... purchase right to purchase 0.50 of a share of ...
(Date:5/28/2015)... York and London (PRWEB) May 28, 2015 ... provider of Computer Aided Engineering software, announced today ... Research, Inc. (PSRI). CD-adapco will provide state-of-the-art engineering ... members will share their expertise and experiences in ... and refining industry members and advance the understanding ...
(Date:5/28/2015)... York, NY (PRWEB) May 28, 2015 ... renewed and enhanced its long term partnership with PTI ... work together to provide clients with custom-tailored method ... the art instruments currently available. The agreement includes a ... companies’ employees across organizational lines. This enables a ...
(Date:5/28/2015)... 2015 Dr. Carl Peck, MD, ... Roger L. Williams, MD, has joined the firm ... Experts are top tier consultants whose expertise and ... to the company’s clients. Premier Experts collaborate to ... successfully develop their medical products, pursue optimal regulatory ...
Breaking Biology Technology:RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2
... Oct. 21 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. ("SemBioSys") ... entered into a definitive agreement to acquire all ... Specialty Ingredients Inc. ("Botaneco") held by SemBioSys and ... an initial 9.48 percent shareholding in Advitech, in ...
... BEIJING, Oct. 20, 2009 Monsanto Company and Huazhong ... the development of novel traits such as higher yield, ... and advance certain technologies developed by Professor Qifa Zhang,s ... "We,re excited to be working with a prominent research ...
... 20 NuVasive, Inc. (Nasdaq: NUVA ... minimally disruptive surgical treatments for the spine, announced today financial ... reported third quarter revenue of $94.9 million, a 41.8% increase ... a 7.3% increase over the $88.5 million for the second ...
Cached Biology Technology:SemBioSys provides an update on Botaneco 2SemBioSys provides an update on Botaneco 3SemBioSys provides an update on Botaneco 4Monsanto and Huazhong Agricultural University Enter Into Collaboration Focusing on Development of Plant Biotechnology 2Monsanto and Huazhong Agricultural University Enter Into Collaboration Focusing on Development of Plant Biotechnology 3NuVasive Reports Third Quarter 2009 Financial Results 2NuVasive Reports Third Quarter 2009 Financial Results 3NuVasive Reports Third Quarter 2009 Financial Results 4NuVasive Reports Third Quarter 2009 Financial Results 5NuVasive Reports Third Quarter 2009 Financial Results 6NuVasive Reports Third Quarter 2009 Financial Results 7NuVasive Reports Third Quarter 2009 Financial Results 8NuVasive Reports Third Quarter 2009 Financial Results 9NuVasive Reports Third Quarter 2009 Financial Results 10NuVasive Reports Third Quarter 2009 Financial Results 11NuVasive Reports Third Quarter 2009 Financial Results 12
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... JOSE, Calif. , May 11, 2015 /PRNewswire/ ... developer of human interface solutions, today announced the ... Vice President and Chief Financial Officer, reporting to ... Ali replaces Synaptics, current Chief Financial Officer, ... December 2014. Mr. Ali brings ...
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an order for ... World Peace Industrial Group (WPI), part of WPG Holdings. WPI ... . Deliveries are planned to take place during Q3 2015 ... China . The order value of 235 ... 1 000 MSEK for 2015.   Jörgen Lantto, acting ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... release is available in German . , ... the 2009 Charles Rodolphe Brupbacher Prize for Cancer Research. Nubia ... tumours such as cervical cancer through human papilloma viruses and ... smoking. The prize from the Charles Rodolphe Brupbacher Foundation has ...
... available in German . The use of ... risk that people may come into contact with it, and ... risk. However, radioactivity is not the only problem related to ... more dangerous to human health. Researchers are still looking for ...
... 2009 An international conference that will explore Darwin,s ... May 25-29. It is being organized to coincide with ... the Origin of Species, (and the 200th anniversaryspecifically, todayof ... of biology," says Ralph Pudritz, director of McMaster,s Origins ...
Cached Biology News:Brupbacher prize to Nubia Munoz and Sir Richard Peto 2Brupbacher prize to Nubia Munoz and Sir Richard Peto 3A pocketful of uranium 2
... the consumable measurement plate for ... individually controlled measurement sites. Each ... liquid flow channel system that ... solution and compound applications necessary ...
... capable of dynamic scheduling, is designed to ... automation workcells easy for lab personnel, yet ... • Users create methods by ... can build a flowchart, you can write ...
... research demands continue to grow, the need ... information has become necessary, especially when discerning ... The innovative C1si Confocal Microscope System gives ... spectral capability not available in conventional confocal ...
... provides complete components including positive and ... of DNA fragmentation in cultured cells ... BrdU in the procedure provides greater ... Results can be analyzed by fluorescence ...
Biology Products: